Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Patent metadata

Field	Value
Publication number	US-8969533-B2
Application number	US-11219108-A
Country	US
Kind code	B2
Filing date	Apr 30, 2008
Priority date	May 4, 2007
Publication date	Mar 3, 2015
Grant date	Mar 3, 2015

Abstract

The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.

First claim

What is claimed is:

1. A method for purification of an inactivated virus or fragmented virus, the method comprising
(a) providing a gradient-forming solution containing a sugar gradient by centrifuging in a continuous ultracentrifuge comprising an ultracentrifugation rotor at least
(i) a first buffered sugar solution comprising a first physiological buffer and
(ii) a second buffered sugar solution having a higher density than the first buffered sugar solution and comprising

a second physiological buffer, which is the same or different from the first physiological buffer,
wherein the concentration of sugar in the first buffered sugar solution has a sucrose equivalent between 35% to 50% (w/w%) and the concentration of sugar in the second buffered sugar solution has a sucrose equivalent between 50% to 65% (w/w%), and the volume ratio of the first buffered sugar solution to the second buffered sugar solution is greater than or equal to 3:1;

(b) adding an inactivated virus or fragmented virus preparation to the sugar gradient;
(c) centrifuging the inactivated virus or fragmented virus preparation and sugar gradient to obtain an inactivated virus or fragmented virus peak pool with a sucrose equivalent between 30% and 54% (w/w%) sucrose; and
(d) extracting the inactivated virus or fragmented virus peak pool to obtain the inactivated virus or fragmented virus.

2. The method of claim 1 , wherein the volume of the gradient-forming solution is between 5% to 100% of the volume of the ultracentrifugation rotor.

3. The method of claim 1 , wherein is the peak pool has a density between 1.13 kg 1 to 1.25 kg/l.

4. The method of claim 1 , wherein at least one of the physiological buffers has a concentration of between 5 mM to 50 mM.

5. The method of claim 4 , wherein at least one of the physiological buffers has a concentration of between 15 mM to 30 mM.

6. The method of claim 5 , wherein at least one of the physiological buffers has a concentration of between 18 mM to 25 mM.

7. The method of claim 1 , wherein the step of centrifuging the virus preparation is performed with a relative centrifugation force of at least 20,000 g.

8. The method of claim 7 , wherein said relative centrifugation force is at least 30,000 g.

9. The method of claim 8 , wherein said relative centrifugation force is at least 90,000 g.

10. The method of claim 1 , wherein the volume ratio of said first buffered sugar solution to said at least a second buffered sugar solution is less than 20:1.

11. The method of claim 10 , wherein said volume ratio is less than 10: 1.

12. The method of claim 11 , wherein said volume ratio is less than 8:1.

13. The method of claim 1 , wherein said volume ratio is between 6:1 to 3:1.

14. The method of claim 1 , wherein said solution containing a sugar gradient comprises two layers.

15. The method of claim 1 , wherein said preparation does not comprise a preclarifier.

16. The method of claim 1 , wherein said at least a first buffered sugar solution comprises a sugar in a concentration range from 40 % to 44% (w/w%) sucrose equivalent.

17. The method of claim 16 , wherein said at least a first buffered sugar solution comprises a sugar in a concentration range of 41% to 43% (w/w%) sucrose equivalent.

18. The method of claim 1 , wherein said at least a second buffered sugar solution comprises a sugar in a concentration range from 52% to 58% (w/w%) sucrose equivalent.

19. The method of claim 18 , wherein said at least a second buffered sugar solution comprises a sugar from 54% to 56% sucrose equivalent.

20. The method of claim 1 , wherein said inactivated virus or fragmented virus is from an orthomyxovirus.

21. The method of claim 20 , wherein said inactivated virus or fragmented virus is from an influenza virus.

22. The method of claim 1 , wherein at least one of the physiological buffers is an amine buffer.

23. The method of claim 1 , wherein is at least one of the physiological buffers is a TRIS buffer.

24. The method of claim 23 , wherein the physiological buffer is TRIS-buffered saline.

25. A method for purification of an inactivated virus or fragmented virus comprising
(a) providing a gradient-forming solution containing a sugar gradient by centrifuging in a continuous ultracentrifuge comprising an ultracentrifugation rotor at least
(i) a first buffered sugar solution having a density of 1.15 kg/l to 1.23 kg/l and
(ii) at least a second buffered sugar solution having a density of 1.23 kg/l to 1.32 kg/l and which is higher than the density of the first buffered solution,
wherein, and the volume ratio of the first buffered sugar solution to the second buffered sugar solution is greater than or equal to 3:1;

(b) adding an inactivated virus or fragmented virus preparation to the sugar gradient;
(c) centrifuging the inactivated virus or fragmented virus preparation and sugar gradient to obtain a peak inactivated virus or fragmented virus pool; and
(d) extracting the peak inactivated virus or fragmented virus pool to obtain the inactivated virus or fragmented virus.

26. The method of claim 1 , wherein the volume of the gradient forming solution is less than 100% of the volume of the ultracentrifuge rotor.

27. The method of claim 26 , wherein the volume of the gradient forming solution is less than 90% of the volume of the ultracentrifuge rotor.

28. The method of claim 1 , wherein the volume of the gradient forming solution is greater than or equal to 50% of the volume of the ultracentrifuge rotor.

29. The method of claim 25 , wherein the volume of the gradient forming solution is less than 100% of the volume of the ultracentrifuge rotor.

30. The method of claim 28 , wherein the volume of the gradient forming solution is less than 90% of the volume of the ultracentrifuge rotor.

31. The method of claim 25 , wherein the volume of the gradient forming solution is greater than or equal to 50% of the volume of the ultracentrifuge rotor.

Assignees

• Reiter Manfred
• Grillberger Leopold
• Mundt Wolfgang
• Mitterer Artur
• Schafhauser Horst
• Baxter Int
• Baxter Healthcare Sa

Inventors

• Reiter Manfred
• Grillberger Leopold
• Mundt Wolfgang
• Mitterer Artur
• Schafhauser Horst

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C12N2760/16251

  Methods of production or purification of viral material · CPC title